Health
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
In a gold-standard model of obesity, treatment with ARD-201 resulted in approximately 19% body weight reduction after 30 days of treatment.ARD-201 was also associated with attenuated weight regain after discontinuation of tirzepatide.In combination with low-dose tirzepatide, ARD-201 improved weight loss compared to high dose tirzepatide alone.Aardvark plans two separate Phase 2 clinical trials for ARD-201: Phase 2 POWER trial to focus on weight rebound in patients discontinuing GLP-1RA therapy,
About this update from Aardvark Therapeutics, Inc.
[{"type":"image","alt":"Aardvark Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Aardvark Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/fe55bd926bdb60296161677c87a21101"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_2n1g9xWdfu1GQlbvtkO7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/fe55bd926bdb60296161677c87a21101","width":300,"height":63}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"In a gold-standard model of obesity, treatment with ARD-201 resulted in approximately 19% body weight reduction after 30 days of treatment.","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"ARD-201 was also associated with attenuated weight regain after discontinuation of tirzepatide.","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"In combination with low-dose tirzepatide, ARD-201 improved weight loss compared to high dose tirzepatide alone.","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"Aardvark plans two separate Phase 2 clinical trials for ARD-201: Phase 2 POWER trial to focus on weight rebound in patients discontinuing GLP-1RA therapy, and Phase 2 STRENGTH trial to focus on weight loss as a monotherapy and in combination with GLP-1RA. ","length":255,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":600,"olType":false},{"type":"text","content":"SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity and obesity-related conditions. Data in the validated diet-induced obesity (DIO) mouse model (a conventional model recognized for its strong translational relevance in the field of glucagon-like peptide-1 receptor agonists (GLP-1RAs)) demonstrated potential applications for ARD-201, including for the attenuation of weight gain after withdrawal from GLP-1RA therapies, as a monotherapy for weight loss without GLP-1RA therapy, as well as for weight loss in combinatio...